Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome

Ya Min Yang, Chen Yang Hsu, Chao Chih Lai, Ming Fang Yen, Paul S. Wikramaratna, Hsiu Hsi Chen, Tsung Hsi Wang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

To date, 1841 cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported worldwide, with 652 deaths. We used a publically available case line list to explore the effect of relevant factors, notably underlying comorbidities, on fatal outcome of Middle East respiratory syndrome (MERS) cases up to the end of October 2016. A Bayesian Weibull proportional hazards regression model was used to assess the effect of comorbidity, age, epidemic period and sex on the fatality rate of MERS cases and its variation across countries. The crude fatality rate of MERS cases was 32.1% (95% credibility interval (CI): 29.9%, 34.3%). Notably, the incremental change of daily death rate was most prominent during the first week since disease onset with an average increase of 13%, but then stabilized in the remaining two weeks when it only increased 3% on average. Neither sex, nor country of infection were found to have a significant impact on fatality rates after taking into account the age and comorbidity status of patients. After adjusting for age, epidemic period, MERS patients with comorbidity had around 4 times the risk for fatal infection than those without (adjusted hazard ratio of 3.74 (95% CI: 2.57, 5.67)).

Original languageEnglish
Article number11307
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Dec 1 2017

Fingerprint

Coronavirus Infections
Comorbidity
Fatal Outcome
Infection
Proportional Hazards Models
Mortality

ASJC Scopus subject areas

  • General

Cite this

Yang, Y. M., Hsu, C. Y., Lai, C. C., Yen, M. F., Wikramaratna, P. S., Chen, H. H., & Wang, T. H. (2017). Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome. Scientific Reports, 7(1), [11307]. https://doi.org/10.1038/s41598-017-10402-1

Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome. / Yang, Ya Min; Hsu, Chen Yang; Lai, Chao Chih; Yen, Ming Fang; Wikramaratna, Paul S.; Chen, Hsiu Hsi; Wang, Tsung Hsi.

In: Scientific Reports, Vol. 7, No. 1, 11307, 01.12.2017.

Research output: Contribution to journalArticle

Yang, Ya Min ; Hsu, Chen Yang ; Lai, Chao Chih ; Yen, Ming Fang ; Wikramaratna, Paul S. ; Chen, Hsiu Hsi ; Wang, Tsung Hsi. / Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{dc80187412394d2d8644ab3e0a3ffab8,
title = "Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome",
abstract = "To date, 1841 cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported worldwide, with 652 deaths. We used a publically available case line list to explore the effect of relevant factors, notably underlying comorbidities, on fatal outcome of Middle East respiratory syndrome (MERS) cases up to the end of October 2016. A Bayesian Weibull proportional hazards regression model was used to assess the effect of comorbidity, age, epidemic period and sex on the fatality rate of MERS cases and its variation across countries. The crude fatality rate of MERS cases was 32.1{\%} (95{\%} credibility interval (CI): 29.9{\%}, 34.3{\%}). Notably, the incremental change of daily death rate was most prominent during the first week since disease onset with an average increase of 13{\%}, but then stabilized in the remaining two weeks when it only increased 3{\%} on average. Neither sex, nor country of infection were found to have a significant impact on fatality rates after taking into account the age and comorbidity status of patients. After adjusting for age, epidemic period, MERS patients with comorbidity had around 4 times the risk for fatal infection than those without (adjusted hazard ratio of 3.74 (95{\%} CI: 2.57, 5.67)).",
author = "Yang, {Ya Min} and Hsu, {Chen Yang} and Lai, {Chao Chih} and Yen, {Ming Fang} and Wikramaratna, {Paul S.} and Chen, {Hsiu Hsi} and Wang, {Tsung Hsi}",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-10402-1",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Impact of Comorbidity on Fatality Rate of Patients with Middle East Respiratory Syndrome

AU - Yang, Ya Min

AU - Hsu, Chen Yang

AU - Lai, Chao Chih

AU - Yen, Ming Fang

AU - Wikramaratna, Paul S.

AU - Chen, Hsiu Hsi

AU - Wang, Tsung Hsi

PY - 2017/12/1

Y1 - 2017/12/1

N2 - To date, 1841 cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported worldwide, with 652 deaths. We used a publically available case line list to explore the effect of relevant factors, notably underlying comorbidities, on fatal outcome of Middle East respiratory syndrome (MERS) cases up to the end of October 2016. A Bayesian Weibull proportional hazards regression model was used to assess the effect of comorbidity, age, epidemic period and sex on the fatality rate of MERS cases and its variation across countries. The crude fatality rate of MERS cases was 32.1% (95% credibility interval (CI): 29.9%, 34.3%). Notably, the incremental change of daily death rate was most prominent during the first week since disease onset with an average increase of 13%, but then stabilized in the remaining two weeks when it only increased 3% on average. Neither sex, nor country of infection were found to have a significant impact on fatality rates after taking into account the age and comorbidity status of patients. After adjusting for age, epidemic period, MERS patients with comorbidity had around 4 times the risk for fatal infection than those without (adjusted hazard ratio of 3.74 (95% CI: 2.57, 5.67)).

AB - To date, 1841 cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported worldwide, with 652 deaths. We used a publically available case line list to explore the effect of relevant factors, notably underlying comorbidities, on fatal outcome of Middle East respiratory syndrome (MERS) cases up to the end of October 2016. A Bayesian Weibull proportional hazards regression model was used to assess the effect of comorbidity, age, epidemic period and sex on the fatality rate of MERS cases and its variation across countries. The crude fatality rate of MERS cases was 32.1% (95% credibility interval (CI): 29.9%, 34.3%). Notably, the incremental change of daily death rate was most prominent during the first week since disease onset with an average increase of 13%, but then stabilized in the remaining two weeks when it only increased 3% on average. Neither sex, nor country of infection were found to have a significant impact on fatality rates after taking into account the age and comorbidity status of patients. After adjusting for age, epidemic period, MERS patients with comorbidity had around 4 times the risk for fatal infection than those without (adjusted hazard ratio of 3.74 (95% CI: 2.57, 5.67)).

UR - http://www.scopus.com/inward/record.url?scp=85029293866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029293866&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-10402-1

DO - 10.1038/s41598-017-10402-1

M3 - Article

AN - SCOPUS:85029293866

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 11307

ER -